Skip to content

Pulse Biosciences

US · PLSE #2388 by market cap Listed 2016
45.55 +1.14 +2.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Founded
2014
CEO
Mr. Paul A. Laviolette
Employees
116
Headquarters
Miami, Florida, United States of America
Fiscal year end
12-31
Website
pulsebiosciences.com

Company profile

Exchange
US
Symbol
PLSE
Market-cap rank
#2388
Listing date
2016-05-18
Market cap
3.35B
Float cap
1.04B
Shares out
73.55M
Float shares
22.88M

Sectors & themes

Medical Instruments & Supplies Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Pulse Biosciences discussion 0 comments

Add a comment